TDMS Study 05158-03 Pathology Tables
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 03 TIME: 02:09:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE PAGE: 1
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: GRUMBEIN, S. CAS: 0001313-27-5
------------------------------------------------------------------------------------------------------------------------------------
REASONS FOR REMOVAL: ALL
REMOVAL DATE RANGE: ALL
TREATMENT GROUPS: INCLUDE ALL
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 03 TIME: 02:09:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: GRUMBEIN, S. CAS: 0001313-27-5
RATS(FISCHER344)
----------------------------
FOR ALL DOSES THE TUMOR RATES IN THE FOLLOWING TISSUES/ORGANS ARE BASED ON NUMBER OF TISSUES EXAMINED.
IN OTHER TISSUES/ORGANS, RATES ARE BASED ON NUMBER OF ANIMALS NECROPSIED.
----------------
Adrenal Cortex
Adrenal Medulla
Bone Marrow
Brain
Clitoral Gland
Clitoral/Preputial Gland
Epididymis
Heart
Islets, Pancreatic
Kidney
Larynx
Liver
Lung
Nose
Ovary
Pancreas
Parathyroid Gland
Pituitary Gland
Preputial Gland
Prostate
Salivary Glands
Spleen
Testes
Thymus
Thyroid Gland
Urinary Bladder
NTP STATISTICAL ANALYSIS OF PRIMARY TUMORS REPORT: PEIRPT08
LAB: Battelle Northwest MOLYBDENUM TRIOXIDE DATE: 04/04/96
EXPERIMENT: 05158 TEST: 03 TIME: 02:09:16
TEST TYPE: CHRONIC CAGES FROM 0000 TO LAST CAGE
CONT: N01-ES-95240 ROUTE: RESPIRATORY EXPOSURE WHOLE BODY NTP C#: 61369C
PATHOLOGIST: GRUMBEIN, S. CAS: 0001313-27-5
SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS
IN THE ANALYSIS OF THE STUDY OF 7-5MOLYBDENUM TRIOXIDE
====================================================================================================
MALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Lung Alveolar/Bronchiolar Adenoma
Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma
Skin Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma
Squamous Cell Papilloma, Papilloma, or Keratoacanthoma
Spleen Fibroma
All Organs Benign Tumors
====================================================================================================
FEMALE RATS
-------------
ORGAN MORPHOLOGY
------- ------------
Adrenal Medulla Pheochromocytoma Benign
Pheochromocytoma: Benign, Complex, Malignant, NOS
Clitoral/Preputial Gland Carcinoma or Adenoma
Mammary Gland Fibroadenoma
Fibroma, Fibroadenoma or Adenoma
Fibroma, Fibroadenoma, Carcinoma, or Adenoma
Pituitary Gland: Pars Distalis or Unspecified Site
Adenoma
====================================================================================================
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 1
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Cortex |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 0/50 (0%) | 1/49 (2%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 9.7% 0.0% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 1/16 (6%) 0/17 (0%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- 665 --- | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.611N (e) P=0.237 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.586N (e) P=0.251 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.629N (e) P=0.239 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.675N | P=0.497N |
|FISHER EXACT | (e) P=0.247 (e) | P=0.500N P=0.495N P=0.495N |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Benign |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 15/50 (30%) 11/50 (22%) 17/50 (34%) 17/50 (34%) | 5/49 (10%) 0/49 (0%) 4/50 (8%) 6/50 (12%) |
|ADJUSTED (b) | 60.4% 66.3% 58.1% 56.7% | 14.3% 0.0% 10.7% 20.7% |
|TERMINAL (d) | 8/17 (47%) 5/10 (50%) 6/16 (38%) 6/17 (35%) | 2/28 (7%) 0/24 (0%) 0/24 (0%) 3/23 (13%) |
|FIRST INCIDENCE (DAYS) | 559 622 525 598 | 680 --- 583 555 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.532N P=0.473 P=0.398 P=0.539 | P=0.093 P=0.055N P=0.563N P=0.363 |
|INCIDENTAL TUMOR | P=0.542 P=0.433N P=0.437 P=0.553N | P=0.165 P=0.048N* P=0.427N P=0.512 |
|LOGISTIC REGRESSION | P=0.476 P=0.503N P=0.430 P=0.566 | P=0.142 P=0.035N* P=0.371N P=0.486 |
|COCHRAN-ARMITAGE | P=0.232 | P=0.143 |
|FISHER EXACT | P=0.247N P=0.415 P=0.415 | P=0.028N* P=0.487N P=0.514 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 2
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma Malignant |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 1/50 (2%) 2/50 (4%) | 0/49 (0%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 8.9% 5.6% 2.6% 9.4% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 0/10 (0%) 0/16 (0%) 1/17 (6%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 629 684 594 692 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.616 P=0.613N P=0.487N P=0.656N | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.553 P=0.525N P=0.507N P=0.693N | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.566 P=0.556N P=0.500N P=0.660N | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.521 | (e) |
|FISHER EXACT | P=0.500N P=0.500N P=0.691N | (e) (e) (e) |
|=================================================================================================================================|
| |
|Adrenal Medulla |
| Pheochromocytoma: Benign, Complex, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 15/50 (30%) 13/50 (26%) 18/50 (36%) 18/50 (36%) | 6/49 (12%) 0/49 (0%) 4/50 (8%) 6/50 (12%) |
|ADJUSTED (b) | 60.4% 70.6% 59.2% 60.6% | 17.6% 0.0% 10.7% 20.7% |
|TERMINAL (d) | 8/17 (47%) 5/10 (50%) 6/16 (38%) 7/17 (41%) | 3/28 (11%) 0/24 (0%) 0/24 (0%) 3/23 (13%) |
|FIRST INCIDENCE (DAYS) | 559 622 525 598 | 680 --- 583 555 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.524N P=0.288 P=0.331 P=0.461 | P=0.143 P=0.032N* P=0.444N P=0.472 |
|INCIDENTAL TUMOR | P=0.546 P=0.583 P=0.353 P=0.537 | P=0.235 P=0.028N* P=0.313N P=0.624 |
|LOGISTIC REGRESSION | P=0.474 P=0.476 P=0.345 P=0.487 | P=0.207 P=0.020N* P=0.268N P=0.598 |
|COCHRAN-ARMITAGE | P=0.225 | P=0.212 |
|FISHER EXACT | P=0.412N P=0.335 P=0.335 | P=0.013N* P=0.357N P=0.606N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 3
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 3/50 (6%) 3/50 (6%) 3/50 (6%) | 2/44 (5%) 6/48 (13%) 5/47 (11%) 1/47 (2%) |
|ADJUSTED (b) | 11.8% 23.8% 18.8% 13.7% | 6.9% 21.2% 17.6% 2.9% |
|TERMINAL (d) | 2/17 (12%) 2/10 (20%) 3/16 (19%) 1/17 (6%) | 1/26 (4%) 4/23 (17%) 3/23 (13%) 0/21 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 660 735 (T) 696 | 716 573 653 637 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.593N P=0.290 P=0.471 P=0.520 | P=0.217N P=0.109 P=0.176 P=0.575N |
|INCIDENTAL TUMOR | P=0.556N P=0.323 P=0.471 P=0.607 | P=0.133N P=0.204 P=0.216 P=0.397N |
|LOGISTIC REGRESSION | P=0.574N P=0.353 P=0.471 P=0.562 | P=0.156N P=0.152 P=0.215 P=0.498N |
|COCHRAN-ARMITAGE | P=0.500 | P=0.141N |
|FISHER EXACT | P=0.500 P=0.500 P=0.500 | P=0.164 P=0.245 P=0.475N |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/50 (6%) 1/50 (2%) 1/50 (2%) | 1/44 (2%) 1/48 (2%) 5/47 (11%) 2/47 (4%) |
|ADJUSTED (b) | 12.2% 21.3% 6.3% 5.9% | 3.8% 3.7% 19.3% 9.5% |
|TERMINAL (d) | 1/17 (6%) 1/10 (10%) 1/16 (6%) 1/17 (6%) | 1/26 (4%) 0/23 (0%) 3/23 (13%) 2/21 (10%) |
|FIRST INCIDENCE (DAYS) | 553 622 735 (T) 735 (T) | 735 (T) 721 721 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.164N P=0.498 P=0.318N P=0.287N | P=0.388 P=0.735 P=0.083 P=0.425 |
|INCIDENTAL TUMOR | P=0.183N P=0.629 P=0.303N P=0.300N | P=0.376 P=0.747 P=0.097 P=0.425 |
|LOGISTIC REGRESSION | P=0.167N P=0.598 P=0.302N P=0.288N | P=0.367 P=0.738 P=0.077 P=0.425 |
|COCHRAN-ARMITAGE | P=0.216N | P=0.479 |
|FISHER EXACT | P=0.661N P=0.309N P=0.309N | P=0.731N P=0.117 P=0.525 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 4
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Clitoral/Preputial Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 5/50 (10%) 6/50 (12%) 4/50 (8%) 4/50 (8%) | 3/44 (7%) 7/48 (15%) 10/47 (21%) 3/47 (6%) |
|ADJUSTED (b) | 23.1% 41.7% 25.0% 19.1% | 10.6% 24.1% 35.0% 12.2% |
|TERMINAL (d) | 3/17 (18%) 3/10 (30%) 4/16 (25%) 2/17 (12%) | 2/26 (8%) 4/23 (17%) 6/23 (26%) 2/21 (10%) |
|FIRST INCIDENCE (DAYS) | 553 622 735 (T) 696 | 716 573 653 637 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.245N P=0.241 P=0.530N P=0.469N | P=0.405N P=0.126 P=0.025 * P=0.559 |
|INCIDENTAL TUMOR | P=0.240N P=0.349 P=0.519N P=0.416N | P=0.307N P=0.223 P=0.033 * P=0.652N |
|LOGISTIC REGRESSION | P=0.227N P=0.352 P=0.496N P=0.428N | P=0.343N P=0.172 P=0.027 * P=0.606 |
|COCHRAN-ARMITAGE | P=0.379N | P=0.265N |
|FISHER EXACT | P=0.500 P=0.500N P=0.500N | P=0.196 P=0.046 * P=0.629N |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 6/50 (12%) 1/49 (2%) 4/49 (8%) | 1/49 (2%) 0/49 (0%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 11.2% 32.4% 6.3% 13.4% | 3.0% 0.0% 4.2% 4.3% |
|TERMINAL (d) | 1/17 (6%) 2/10 (20%) 1/16 (6%) 1/17 (6%) | 0/28 (0%) 0/24 (0%) 1/24 (4%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 581 581 735 (T) 567 | 716 --- 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.450N P=0.124 P=0.308N P=0.569 | P=0.519 P=0.533N P=0.725 P=0.711 |
|INCIDENTAL TUMOR | P=0.576 P=0.200 P=0.330N P=0.462 | P=0.510 P=0.531N P=0.751 P=0.700 |
|LOGISTIC REGRESSION | P=0.572N P=0.202 P=0.309N P=0.489 | P=0.509 P=0.516N P=0.738 P=0.712 |
|COCHRAN-ARMITAGE | P=0.587 | P=0.564 |
|FISHER EXACT | P=0.243 P=0.316N P=0.489 | P=0.500N P=0.747N P=0.747N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 5
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 2/49 (4%) 4/49 (8%) | 0/49 (0%) 0/49 (0%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 4.2% 20.0% 12.5% 20.0% | 0.0% 0.0% 0.0% 3.1% |
|TERMINAL (d) | 0/17 (0%) 2/10 (20%) 2/16 (13%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 678 735 (T) 735 (T) 715 | --- --- --- 652 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.202 P=0.346 P=0.476 P=0.207 | P=0.188 (e) (e) P=0.446 |
|INCIDENTAL TUMOR | P=0.239 P=0.397 P=0.505 P=0.297 | P=0.171 (e) (e) P=0.433 |
|LOGISTIC REGRESSION | P=0.214 P=0.395 P=0.497 P=0.219 | P=0.226 (e) (e) P=0.506 |
|COCHRAN-ARMITAGE | P=0.123 | P=0.223 |
|FISHER EXACT | P=0.500 P=0.492 P=0.175 | (e) (e) P=0.505 |
|=================================================================================================================================|
| |
|Islets, Pancreatic |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 7/50 (14%) 3/49 (6%) 8/49 (16%) | 1/49 (2%) 0/49 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 14.9% 40.8% 18.8% 31.3% | 3.0% 0.0% 4.2% 7.3% |
|TERMINAL (d) | 1/17 (6%) 3/10 (30%) 3/16 (19%) 3/17 (18%) | 0/28 (0%) 0/24 (0%) 1/24 (4%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 581 581 735 (T) 567 | 716 --- 735 (T) 652 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.346 P=0.119 P=0.517N P=0.244 | P=0.197 P=0.533N P=0.725 P=0.419 |
|INCIDENTAL TUMOR | P=0.242 P=0.205 P=0.517N P=0.228 | P=0.181 P=0.531N P=0.751 P=0.399 |
|LOGISTIC REGRESSION | P=0.267 P=0.201 P=0.503N P=0.192 | P=0.212 P=0.516N P=0.738 P=0.481 |
|COCHRAN-ARMITAGE | P=0.174 | P=0.244 |
|FISHER EXACT | P=0.262 P=0.511N P=0.168 | P=0.500N P=0.747N P=0.508 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 6
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 2/50 (4%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 5.6% 5.3% 11.8% 11.8% | 0.0% 0.0% 0.0% 4.3% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 1/16 (6%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 729 675 729 735 (T) | --- --- --- 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.480 P=0.678 P=0.480 P=0.500 | P=0.202 (e) (e) P=0.461 |
|INCIDENTAL TUMOR | P=0.546 P=0.727N P=0.532 P=0.568 | P=0.202 (e) (e) P=0.461 |
|LOGISTIC REGRESSION | P=0.500 P=0.712 P=0.489 P=0.519 | P=0.202 (e) (e) P=0.461 |
|COCHRAN-ARMITAGE | P=0.395 | P=0.222 |
|FISHER EXACT | P=0.753N P=0.500 P=0.500 | (e) (e) P=0.500 |
|=================================================================================================================================|
| |
|Kidney: Renal Tubule |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 2/50 (4%) | 0/50 (0%) 1/49 (2%) 1/50 (2%) 1/50 (2%) |
|ADJUSTED (b) | 5.6% 5.3% 11.8% 11.8% | 0.0% 4.2% 3.6% 4.3% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 1/16 (6%) 2/17 (12%) | 0/28 (0%) 1/24 (4%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 729 675 729 735 (T) | --- 735 (T) 721 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.480 P=0.678 P=0.480 P=0.500 | P=0.461 P=0.469 P=0.486 P=0.461 |
|INCIDENTAL TUMOR | P=0.546 P=0.727N P=0.532 P=0.568 | P=0.449 P=0.469 P=0.514 P=0.461 |
|LOGISTIC REGRESSION | P=0.500 P=0.712 P=0.489 P=0.519 | P=0.448 P=0.469 P=0.481 P=0.461 |
|COCHRAN-ARMITAGE | P=0.395 | P=0.502 |
|FISHER EXACT | P=0.753N P=0.500 P=0.500 | P=0.495 P=0.500 P=0.500 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 7
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 1/50 (2%) 1/50 (2%) 2/50 (4%) | 0/50 (0%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 11.8% 10.0% 6.3% 11.8% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/17 (12%) 1/10 (10%) 1/16 (6%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 735 (T) 735 (T) 735 (T) | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.596 P=0.686N P=0.522N P=0.700 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.596 P=0.686N P=0.522N P=0.700 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.596 P=0.686N P=0.522N P=0.700 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.521 | (e) |
|FISHER EXACT | P=0.500N P=0.500N P=0.691N | (e) (e) (e) |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma or Hepatocellular Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) 3/50 (6%) | 1/50 (2%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 11.8% 13.8% 6.3% 14.0% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/17 (12%) 1/10 (10%) 1/16 (6%) 2/17 (12%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 634 735 (T) 621 | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.475 P=0.527 P=0.522N P=0.518 | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.374 P=0.561 P=0.522N P=0.449 | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.481 P=0.598 P=0.522N P=0.562 | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.373 | P=0.499N |
|FISHER EXACT | P=0.691N P=0.500N P=0.500 | P=0.505N P=0.500N P=0.500N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 8
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Liver |
| Hepatocellular Carcinoma, Hepatocellular Adenoma, or Hepatoblastoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 2/50 (4%) 1/50 (2%) 3/50 (6%) | 1/50 (2%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 11.8% 13.8% 6.3% 14.0% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 2/17 (12%) 1/10 (10%) 1/16 (6%) 2/17 (12%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 634 735 (T) 621 | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.475 P=0.527 P=0.522N P=0.518 | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.374 P=0.561 P=0.522N P=0.449 | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.481 P=0.598 P=0.522N P=0.562 | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.373 | P=0.499N |
|FISHER EXACT | P=0.691N P=0.500N P=0.500 | P=0.505N P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 3/50 (6%) | 0/50 (0%) 1/50 (2%) 0/50 (0%) 2/50 (4%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 14.8% | 0.0% 4.2% 0.0% 7.1% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 1/17 (6%) | 0/28 (0%) 1/24 (4%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | --- --- --- 717 | --- 735 (T) --- 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.017 * (e) (e) P=0.133 | P=0.124 P=0.469 (e) P=0.197 |
|INCIDENTAL TUMOR | P=0.027 * (e) (e) P=0.197 | P=0.192 P=0.469 (e) P=0.354 |
|LOGISTIC REGRESSION | P=0.017 * (e) (e) P=0.140 | P=0.135 P=0.469 (e) P=0.234 |
|COCHRAN-ARMITAGE | P=0.009 ** | P=0.149 |
|FISHER EXACT | (e) (e) P=0.121 | P=0.500 (e) P=0.247 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 9
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Lung |
| Alveolar/Bronchiolar Carcinoma or Alveolar/Bronchiolar Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 1/50 (2%) 4/50 (8%) | 0/50 (0%) 2/50 (4%) 0/50 (0%) 2/50 (4%) |
|ADJUSTED (b) | 0.0% 5.3% 4.3% 17.4% | 0.0% 8.3% 0.0% 7.1% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 1/17 (6%) | 0/28 (0%) 2/24 (8%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | --- 675 677 665 | --- 735 (T) --- 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.048 * P=0.453 P=0.492 P=0.080 | P=0.241 P=0.204 (e) P=0.197 |
|INCIDENTAL TUMOR | P=0.071 P=0.533 P=0.533 P=0.130 | P=0.317 P=0.204 (e) P=0.354 |
|LOGISTIC REGRESSION | P=0.034 * P=0.473 P=0.502 P=0.078 | P=0.250 P=0.204 (e) P=0.234 |
|COCHRAN-ARMITAGE | P=0.019 * | P=0.280 |
|FISHER EXACT | P=0.500 P=0.500 P=0.059 | P=0.247 (e) P=0.247 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 0/50 (0%) 3/50 (6%) 3/50 (6%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 0.0% 10.6% 12.5% 2.9% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 2/24 (8%) 3/24 (13%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | --- 618 735 (T) 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.595N P=0.101 P=0.094 P=0.459 |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.472N P=0.164 P=0.094 P=0.788 |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.571N P=0.118 P=0.094 P=0.496 |
|COCHRAN-ARMITAGE | (e) | P=0.539N |
|FISHER EXACT | (e) (e) (e) | P=0.121 P=0.121 P=0.500 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 10
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 2/50 (4%) 2/50 (4%) 3/50 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 2.1% 8.3% 6.6% 11.3% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 2/24 (8%) 1/24 (4%) 2/23 (9%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 464 735 (T) 615 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.233 P=0.469 P=0.476 P=0.260 |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.336 P=0.431 P=0.566 P=0.381 |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.277 P=0.484 P=0.482 P=0.301 |
|COCHRAN-ARMITAGE | (e) | P=0.274 |
|FISHER EXACT | (e) (e) (e) | P=0.500 P=0.500 P=0.309 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 5/50 (10%) 5/50 (10%) 3/50 (6%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 0.0% | 2.1% 18.8% 18.8% 11.3% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 4/24 (17%) 4/24 (17%) 2/23 (9%) |
|FIRST INCIDENCE (DAYS) | --- --- --- --- | 464 618 615 636 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | (e) (e) (e) (e) | P=0.499 P=0.083 P=0.082 P=0.260 |
|INCIDENTAL TUMOR | (e) (e) (e) (e) | P=0.565N P=0.108 P=0.108 P=0.381 |
|LOGISTIC REGRESSION | (e) (e) (e) (e) | P=0.555 P=0.102 P=0.104 P=0.301 |
|COCHRAN-ARMITAGE | (e) | P=0.570 |
|FISHER EXACT | (e) (e) (e) | P=0.102 P=0.102 P=0.309 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 11
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroadenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 1/50 (2%) | 22/50 (44%) 32/50 (64%) 28/50 (56%) 18/50 (36%) |
|ADJUSTED (b) | 0.0% 0.0% 10.0% 2.4% | 61.8% 83.5% 76.4% 63.6% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 15/28 (54%) 18/24 (75%) 16/24 (67%) 13/23 (57%) |
|FIRST INCIDENCE (DAYS) | --- --- 706 598 | 534 485 464 618 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.452 (e) P=0.234 P=0.536 | P=0.165N P=0.014 * P=0.073 P=0.580 |
|INCIDENTAL TUMOR | P=0.441 (e) P=0.273 P=0.388 | P=0.069N P=0.012 * P=0.127 P=0.500N |
|LOGISTIC REGRESSION | P=0.411 (e) P=0.237 P=0.506 | P=0.062N P=0.023 * P=0.126 P=0.529N |
|COCHRAN-ARMITAGE | P=0.383 | P=0.034N* |
|FISHER EXACT | (e) P=0.247 P=0.500 | P=0.035 * P=0.159 P=0.270N |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 1/50 (2%) | 22/50 (44%) 33/50 (66%) 29/50 (58%) 19/50 (38%) |
|ADJUSTED (b) | 0.0% 0.0% 10.0% 2.4% | 61.8% 84.0% 79.4% 64.7% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 15/28 (54%) 18/24 (75%) 17/24 (71%) 13/23 (57%) |
|FIRST INCIDENCE (DAYS) | --- --- 706 598 | 534 485 464 618 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.452 (e) P=0.234 P=0.536 | P=0.205N P=0.010 ** P=0.049 * P=0.492 |
|INCIDENTAL TUMOR | P=0.441 (e) P=0.273 P=0.388 | P=0.076N P=0.010 * P=0.086 P=0.532N |
|LOGISTIC REGRESSION | P=0.411 (e) P=0.237 P=0.506 | P=0.077N P=0.015 * P=0.086 P=0.580 |
|COCHRAN-ARMITAGE | P=0.383 | P=0.044N* |
|FISHER EXACT | (e) P=0.247 P=0.500 | P=0.022 * P=0.115 P=0.342N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 12
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Mammary Gland |
| Fibroma, Fibroadenoma, Carcinoma, or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 1/50 (2%) | 23/50 (46%) 33/50 (66%) 30/50 (60%) 20/50 (40%) |
|ADJUSTED (b) | 0.0% 0.0% 10.0% 2.4% | 62.6% 84.0% 79.9% 68.2% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 15/28 (54%) 18/24 (75%) 17/24 (71%) 14/23 (61%) |
|FIRST INCIDENCE (DAYS) | --- --- 706 598 | 464 485 464 618 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.452 (e) P=0.234 P=0.536 | P=0.235N P=0.016 * P=0.054 P=0.486 |
|INCIDENTAL TUMOR | P=0.441 (e) P=0.273 P=0.388 | P=0.084N P=0.016 * P=0.098 P=0.540N |
|LOGISTIC REGRESSION | P=0.411 (e) P=0.237 P=0.506 | P=0.084N P=0.029 * P=0.099 P=0.533N |
|COCHRAN-ARMITAGE | P=0.383 | P=0.053N |
|FISHER EXACT | (e) P=0.247 P=0.500 | P=0.035 * P=0.115 P=0.343N |
|=================================================================================================================================|
| |
|Oral Cavity (Oral Mucosa, Tongue, Pharynx, Tooth, Gingiva) |
| Squamous Cell Carcinoma, Papilloma Squamous, or Papilloma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 1/50 (2%) 1/50 (2%) | 2/50 (4%) 0/50 (0%) 1/50 (2%) 0/50 (0%) |
|ADJUSTED (b) | 5.9% 0.0% 2.6% 4.5% | 7.1% 0.0% 3.7% 0.0% |
|TERMINAL (d) | 1/17 (6%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 2/28 (7%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) --- 594 715 | 735 (T) --- 729 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.617 P=0.606N P=0.758N P=0.750N | P=0.307N P=0.272N P=0.544N P=0.282N |
|INCIDENTAL TUMOR | P=0.581 P=0.606N P=0.754 P=0.696N | P=0.313N P=0.272N P=0.528N P=0.282N |
|LOGISTIC REGRESSION | P=0.593 P=0.606N P=0.762N P=0.737N | P=0.311N P=0.272N P=0.548N P=0.282N |
|COCHRAN-ARMITAGE | P=0.559 | P=0.276N |
|FISHER EXACT | P=0.500N P=0.753N P=0.753N | P=0.247N P=0.500N P=0.247N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 13
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Pancreas |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 1/50 (2%) | 0/49 (0%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.9% 10.0% 12.5% 4.8% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 1/10 (10%) 2/16 (13%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 735 (T) 735 (T) 717 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.561N P=0.640 P=0.478 P=0.749N | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.539N P=0.640 P=0.478 P=0.696N | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.553N P=0.640 P=0.478 P=0.738N | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.636N | (e) |
|FISHER EXACT | P=0.753N P=0.500 P=0.753N | (e) (e) (e) |
|=================================================================================================================================|
| |
|Pituitary Gland: Pars Distalis or Unspecified Site |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 37/49 (76%) 39/50 (78%) 40/50 (80%) 36/48 (75%) | 43/49 (88%) 39/50 (78%) 40/50 (80%) 38/50 (76%) |
|ADJUSTED (b) | 89.6% 100.0% 97.4% 97.0% | 97.7% 86.1% 88.6% 84.2% |
|TERMINAL (d) | 13/17 (76%) 10/10 (100%) 15/16 (94%) 16/17 (94%) | 27/28 (96%) 18/24 (75%) 19/24 (79%) 16/23 (70%) |
|FIRST INCIDENCE (DAYS) | 425 274 454 497 | 534 485 464 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.071N P=0.054 P=0.373 P=0.331N | P=0.397 P=0.467 P=0.414 P=0.390 |
|INCIDENTAL TUMOR | P=0.329N P=0.409 P=0.286 P=0.575 | P=0.167N P=0.067N P=0.253N P=0.119N |
|LOGISTIC REGRESSION | P=0.319N P=0.366 P=0.381 P=0.505N | P=0.203N P=0.143N P=0.246N P=0.032N* |
|COCHRAN-ARMITAGE | P=0.462N | P=0.177N |
|FISHER EXACT | P=0.478 P=0.384 P=0.570N | P=0.154N P=0.220N P=0.104N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 14
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 0/50 (0%) 0/50 (0%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 18.2% 0.0% 0.0% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 1/10 (10%) 0/16 (0%) 0/17 (0%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- 730 --- --- | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.354N P=0.142 (e) (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.321N P=0.198 (e) (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.349N P=0.145 (e) (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.392N | P=0.500N |
|FISHER EXACT | P=0.247 (e) (e) | P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Skin |
| Basal Cell Carcinoma, Basal Cell Adenoma, Basosquamous Tumor (benign, |
| malignant or NOS), or Trichoepithelioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 2/50 (4%) 1/50 (2%) 0/50 (0%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 18.2% 2.6% 0.0% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 1/10 (10%) 0/16 (0%) 0/17 (0%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- 730 585 --- | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.334N P=0.142 P=0.516 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.362N P=0.198 P=0.500 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.350N P=0.145 P=0.508 (e) | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.383N | P=0.500N |
|FISHER EXACT | P=0.247 P=0.500 (e) | P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 15
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Basal or Sq. Cell Carcinoma, Carcinoma, Basosq. Tumor (M or B), Basal |
| Cell Adenoma, Adenoma, Papilloma, Sq Papilloma, Keratoacanthoma, Trichoepithelioma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 6/50 (12%) 2/50 (4%) 5/50 (10%) | 2/50 (4%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 8.9% 35.5% 8.0% 22.7% | 7.1% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 1/10 (10%) 0/16 (0%) 3/17 (18%) | 2/28 (7%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 629 553 585 618 | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.480 P=0.060 P=0.682N P=0.256 | P=0.284N P=0.272N P=0.272N P=0.282N |
|INCIDENTAL TUMOR | P=0.436 P=0.127 P=0.684N P=0.185 | P=0.284N P=0.272N P=0.272N P=0.282N |
|LOGISTIC REGRESSION | P=0.437 P=0.081 P=0.693N P=0.255 | P=0.284N P=0.272N P=0.272N P=0.282N |
|COCHRAN-ARMITAGE | P=0.340 | P=0.262N |
|FISHER EXACT | P=0.134 P=0.691N P=0.218 | P=0.247N P=0.247N P=0.247N |
|=================================================================================================================================|
| |
|Skin |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/50 (6%) 3/50 (6%) 4/50 (8%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 13.2% 14.7% 15.5% 20.1% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 2/16 (13%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 665 629 653 696 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.561 P=0.511 P=0.648 P=0.540 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.564N P=0.591N P=0.623N P=0.589N | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.538 P=0.664N P=0.661N P=0.576 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.413 | (e) |
|FISHER EXACT | P=0.661N P=0.661N P=0.500 | (e) (e) (e) |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 16
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Fibroma, Fibrosarcoma, Sarcoma, Myxoma, Myxosarcoma, or Fibrous Histiocytoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 3/50 (6%) 3/50 (6%) 6/50 (12%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 13.2% 14.7% 15.5% 23.7% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 2/16 (13%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 665 629 653 406 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.253 P=0.511 P=0.648 P=0.287 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.239 P=0.591N P=0.623N P=0.322 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.175 P=0.664N P=0.661N P=0.252 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.136 | (e) |
|FISHER EXACT | P=0.661N P=0.661N P=0.243 | (e) (e) (e) |
|=================================================================================================================================|
| |
|Skin |
| Fibrosarcoma, Sarcoma, Myxosarcoma, or Fibrous Histiocytoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 1/50 (2%) 0/50 (0%) 2/50 (4%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 4.0% 0.0% 4.5% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- 629 --- 406 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.185 P=0.457 (e) P=0.253 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.035 * P=0.527 (e) P=0.094 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.162 P=0.501 (e) P=0.276 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.149 | (e) |
|FISHER EXACT | P=0.500 (e) P=0.247 | (e) (e) (e) |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 17
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Keratoacanthoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 4/50 (8%) 1/50 (2%) 2/50 (4%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.9% 21.1% 5.6% 11.8% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 0/10 (0%) 0/16 (0%) 2/17 (12%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 553 727 735 (T) | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.504N P=0.108 P=0.754 P=0.500 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.456N P=0.184 P=0.749N P=0.500 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.497N P=0.133 P=0.759 P=0.500 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.591N | (e) |
|FISHER EXACT | P=0.181 P=0.753N P=0.500 | (e) (e) (e) |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 2/50 (4%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 3.2% 0.0% 0.0% 6.1% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 629 --- --- 618 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.262 P=0.543N P=0.482N P=0.572 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.141 P=0.473N P=0.500N P=0.438 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.188 P=0.499N P=0.500N P=0.499 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.186 | (e) |
|FISHER EXACT | P=0.500N P=0.500N P=0.500 | (e) (e) (e) |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 18
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Carcinoma, Basal Cell Carcinoma, Basosquamous Tumor |
| (malignant or NOS), or Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 2/50 (4%) 0/50 (0%) 2/50 (4%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 3.2% 18.2% 0.0% 6.1% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 1/10 (10%) 0/16 (0%) 0/17 (0%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 629 730 --- 618 | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.550 P=0.366 P=0.482N P=0.572 | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.474 P=0.475 P=0.500N P=0.438 | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.499 P=0.424 P=0.500N P=0.499 | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.454 | P=0.500N |
|FISHER EXACT | P=0.500 P=0.500N P=0.500 | P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma, Papilloma, Squamous Cell Carcinoma or Keratoacanthoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 5/50 (10%) 1/50 (2%) 5/50 (10%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 8.9% 29.0% 5.6% 22.7% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 1/10 (10%) 0/16 (0%) 3/17 (18%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 629 553 727 618 | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.377 P=0.117 P=0.496N P=0.256 | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.347 P=0.200 P=0.488N P=0.185 | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.348 P=0.155 P=0.496N P=0.255 | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.254 | P=0.500N |
|FISHER EXACT | P=0.218 P=0.500N P=0.218 | P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 19
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Skin |
| Squamous Cell Papilloma, Papilloma, or Keratoacanthoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 5/50 (10%) 1/50 (2%) 3/50 (6%) | 1/50 (2%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 5.9% 29.0% 5.6% 17.6% | 3.6% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 1/10 (10%) 0/16 (0%) 3/17 (18%) | 1/28 (4%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 553 727 735 (T) | 735 (T) --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.610 P=0.048 * P=0.754 P=0.300 | P=0.521N P=0.531N P=0.531N P=0.539N |
|INCIDENTAL TUMOR | P=0.569N P=0.086 P=0.749N P=0.300 | P=0.521N P=0.531N P=0.531N P=0.539N |
|LOGISTIC REGRESSION | P=0.591N P=0.063 P=0.759 P=0.300 | P=0.521N P=0.531N P=0.531N P=0.539N |
|COCHRAN-ARMITAGE | P=0.517 | P=0.500N |
|FISHER EXACT | P=0.102 P=0.753N P=0.309 | P=0.500N P=0.500N P=0.500N |
|=================================================================================================================================|
| |
|Spleen |
| Fibroma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 2/50 (4%) | 0/49 (0%) 0/49 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 0.0% 0.0% 0.0% 6.8% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | --- --- --- 679 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.078 (e) (e) P=0.292 | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.098 (e) (e) P=0.376 | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.051 (e) (e) P=0.247 | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.042 * | (e) |
|FISHER EXACT | (e) (e) P=0.247 | (e) (e) (e) |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 20
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Testes |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 39/50 (78%) 32/50 (64%) 36/50 (72%) 38/50 (76%) | |
|ADJUSTED (b) | 97.3% 96.5% 97.1% 100.0% | |
|TERMINAL (d) | 16/17 (94%) 9/10 (90%) 15/16 (94%) 17/17 (100%)| |
|FIRST INCIDENCE (DAYS) | 413 469 525 567 | |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.178N P=0.325 P=0.404N P=0.296N | |
|INCIDENTAL TUMOR | P=0.564 P=0.224N P=0.307N P=0.389N | |
|LOGISTIC REGRESSION | P=0.462N P=0.191N P=0.273N P=0.336N | |
|COCHRAN-ARMITAGE | P=0.358 | |
|FISHER EXACT | P=0.093N P=0.322N P=0.500N | |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 5/50 (10%) 8/50 (16%) 3/50 (6%) | 3/49 (6%) 8/49 (16%) 6/50 (12%) 3/50 (6%) |
|ADJUSTED (b) | 11.5% 33.4% 26.8% 13.3% | 9.6% 31.3% 22.4% 9.4% |
|TERMINAL (d) | 1/17 (6%) 2/10 (20%) 2/16 (13%) 1/17 (6%) | 1/28 (4%) 7/24 (29%) 4/24 (17%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 586 629 454 602 | 716 674 706 555 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.263N P=0.188 P=0.121 P=0.613N | P=0.361N P=0.059 P=0.183 P=0.571 |
|INCIDENTAL TUMOR | P=0.422N P=0.300 P=0.099 P=0.581 | P=0.339N P=0.059 P=0.216 P=0.658 |
|LOGISTIC REGRESSION | P=0.367N P=0.275 P=0.101 P=0.651N | P=0.339N P=0.056 P=0.179 P=0.663N |
|COCHRAN-ARMITAGE | P=0.402N | P=0.252N |
|FISHER EXACT | P=0.357 P=0.100 P=0.661N | P=0.100 P=0.254 P=0.651N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 21
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 4/50 (8%) 0/50 (0%) 1/50 (2%) 3/50 (6%) | 3/49 (6%) 1/49 (2%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | 22.2% 0.0% 4.5% 15.2% | 10.7% 4.2% 4.2% 8.7% |
|TERMINAL (d) | 3/17 (18%) 0/10 (0%) 0/16 (0%) 2/17 (12%) | 3/28 (11%) 1/24 (4%) 1/24 (4%) 2/23 (9%) |
|FIRST INCIDENCE (DAYS) | 729 --- 693 693 | 735 (T) 735 (T) 735 (T) 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.546 P=0.146N P=0.196N P=0.487N | P=0.602 P=0.360N P=0.360N P=0.591N |
|INCIDENTAL TUMOR | P=0.596 P=0.111N P=0.169N P=0.408N | P=0.602 P=0.360N P=0.360N P=0.591N |
|LOGISTIC REGRESSION | P=0.566 P=0.122N P=0.178N P=0.439N | P=0.602 P=0.360N P=0.360N P=0.591N |
|COCHRAN-ARMITAGE | P=0.445 | P=0.608N |
|FISHER EXACT | P=0.059N P=0.181N P=0.500N | P=0.309N P=0.301N P=0.490N |
|=================================================================================================================================|
| |
|Thyroid Gland: C-Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 7/50 (14%) 5/50 (10%) 9/50 (18%) 6/50 (12%) | 6/49 (12%) 9/49 (18%) 7/50 (14%) 5/50 (10%) |
|ADJUSTED (b) | 32.1% 33.4% 30.1% 27.0% | 19.7% 35.4% 26.3% 17.7% |
|TERMINAL (d) | 4/17 (24%) 2/10 (20%) 2/16 (13%) 3/17 (18%) | 4/28 (14%) 8/24 (33%) 5/24 (21%) 3/23 (13%) |
|FIRST INCIDENCE (DAYS) | 586 629 454 602 | 716 674 706 555 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.332N P=0.569 P=0.401 P=0.455N | P=0.395N P=0.180 P=0.389 P=0.617 |
|INCIDENTAL TUMOR | P=0.449N P=0.513N P=0.395 P=0.494N | P=0.376N P=0.182 P=0.434 P=0.573N |
|LOGISTIC REGRESSION | P=0.415N P=0.533N P=0.395 P=0.412N | P=0.399N P=0.171 P=0.392 P=0.576N |
|COCHRAN-ARMITAGE | P=0.521N | P=0.266N |
|FISHER EXACT | P=0.380N P=0.393 P=0.500N | P=0.288 P=0.516 P=0.486N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 22
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 0/50 (0%) 0/50 (0%) 2/50 (4%) 2/50 (4%) | 0/49 (0%) 1/49 (2%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 0.0% 0.0% 12.5% 10.2% | 0.0% 4.2% 0.0% 4.3% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 2/16 (13%) 1/17 (6%) | 0/28 (0%) 1/24 (4%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | --- --- 735 (T) 715 | --- 735 (T) --- 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.184 (e) P=0.223 P=0.250 | P=0.433 P=0.469 (e) P=0.461 |
|INCIDENTAL TUMOR | P=0.205 (e) P=0.223 P=0.304 | P=0.433 P=0.469 (e) P=0.461 |
|LOGISTIC REGRESSION | P=0.191 (e) P=0.223 P=0.263 | P=0.433 P=0.469 (e) P=0.461 |
|COCHRAN-ARMITAGE | P=0.136 | P=0.468 |
|FISHER EXACT | (e) P=0.247 P=0.247 | P=0.500 (e) P=0.505 |
|=================================================================================================================================|
| |
|Thyroid Gland: Follicular Cell |
| Carcinoma or Adenoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | |
|----------- | | |
|OVERALL (a) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 3/50 (6%) | 1/49 (2%) 2/49 (4%) 0/50 (0%) 1/50 (2%) |
|ADJUSTED (b) | 5.9% 5.3% 12.5% 15.8% | 3.6% 8.0% 0.0% 4.3% |
|TERMINAL (d) | 1/17 (6%) 0/10 (0%) 2/16 (13%) 2/17 (12%) | 1/28 (4%) 1/24 (4%) 0/24 (0%) 1/23 (4%) |
|FIRST INCIDENCE (DAYS) | 735 (T) 675 735 (T) 715 | 735 (T) 727 --- 735 (T) |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.265 P=0.674 P=0.478 P=0.313 | P=0.621N P=0.443 P=0.531N P=0.718 |
|INCIDENTAL TUMOR | P=0.296 P=0.724 P=0.478 P=0.357 | P=0.632N P=0.446 P=0.531N P=0.718 |
|LOGISTIC REGRESSION | P=0.280 P=0.709 P=0.478 P=0.334 | P=0.634N P=0.439 P=0.531N P=0.718 |
|COCHRAN-ARMITAGE | P=0.188 | P=0.571N |
|FISHER EXACT | P=0.753N P=0.500 P=0.309 | P=0.500 P=0.495N P=0.747N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 23
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # # |
|----------- | | |
|OVERALL (a) | | 6/50 (12%) 8/50 (16%) 8/50 (16%) 8/50 (16%) |
|ADJUSTED (b) | | 16.9% 27.9% 27.6% 28.1% |
|TERMINAL (d) | | 2/28 (7%) 5/24 (21%) 5/24 (21%) 5/23 (22%) |
|FIRST INCIDENCE (DAYS) | | 638 663 326 560 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.299 P=0.274 P=0.294 P=0.250 |
|INCIDENTAL TUMOR | | P=0.324 P=0.337 P=0.375 P=0.443 |
|LOGISTIC REGRESSION | | P=0.395 P=0.345 P=0.381 P=0.354 |
|COCHRAN-ARMITAGE | | P=0.430 |
|FISHER EXACT | | P=0.387 P=0.387 P=0.387 |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # # |
|----------- | | |
|OVERALL (a) | | 0/50 (0%) 0/50 (0%) 1/50 (2%) 2/50 (4%) |
|ADJUSTED (b) | | 0.0% 0.0% 3.7% 5.6% |
|TERMINAL (d) | | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | | --- --- 729 619 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.070 (e) P=0.486 P=0.199 |
|INCIDENTAL TUMOR | | P=0.170 (e) P=0.514 P=0.593 |
|LOGISTIC REGRESSION | | P=0.092 (e) P=0.474 P=0.227 |
|COCHRAN-ARMITAGE | | P=0.090 |
|FISHER EXACT | | (e) P=0.500 P=0.247 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 24
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|Uterus |
| Sarcoma Stromal or Polyp Stromal |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | | # # # # |
|----------- | | |
|OVERALL (a) | | 6/50 (12%) 8/50 (16%) 8/50 (16%) 10/50 (20%) |
|ADJUSTED (b) | | 16.9% 27.9% 27.6% 32.1% |
|TERMINAL (d) | | 2/28 (7%) 5/24 (21%) 5/24 (21%) 5/23 (22%) |
|FIRST INCIDENCE (DAYS) | | 638 663 326 560 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | | P=0.123 P=0.274 P=0.294 P=0.116 |
|INCIDENTAL TUMOR | | P=0.170 P=0.337 P=0.375 P=0.360 |
|LOGISTIC REGRESSION | | P=0.189 P=0.345 P=0.381 P=0.197 |
|COCHRAN-ARMITAGE | | P=0.208 |
|FISHER EXACT | | P=0.387 P=0.387 P=0.207 |
|=================================================================================================================================|
| |
|Zymbal's Gland |
| Carcinoma |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 2/50 (4%) 0/50 (0%) 1/50 (2%) 0/50 (0%) | 1/50 (2%) 1/50 (2%) 2/50 (4%) 0/50 (0%) |
|ADJUSTED (b) | 5.7% 0.0% 6.3% 0.0% | 2.0% 2.2% 5.6% 0.0% |
|TERMINAL (d) | 0/17 (0%) 0/10 (0%) 1/16 (6%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 520 --- 735 (T) --- | 433 583 583 --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.241N P=0.274N P=0.503N P=0.212N | P=0.356N P=0.756N P=0.476 P=0.496N |
|INCIDENTAL TUMOR | P=0.278N P=0.198N P=0.521N P=0.261N | P=0.228N P=0.672N P=0.591 P=0.500N |
|LOGISTIC REGRESSION | P=0.277N P=0.207N P=0.500N P=0.225N | P=0.361N P=0.677 P=0.465 P=0.658N |
|COCHRAN-ARMITAGE | P=0.276N | P=0.325N |
|FISHER EXACT | P=0.247N P=0.500N P=0.247N | P=0.753N P=0.500 P=0.500N |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 25
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Leukemia: Lymphocytic, Monocytic, Mononuclear, or Undifferentiated |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 35/50 (70%) 31/50 (62%) 28/50 (56%) 32/50 (64%) | 18/50 (36%) 19/50 (38%) 13/50 (26%) 20/50 (40%) |
|ADJUSTED (b) | 86.0% 85.5% 77.2% 82.1% | 45.8% 48.8% 39.5% 50.7% |
|TERMINAL (d) | 12/17 (71%) 6/10 (60%) 9/16 (56%) 11/17 (65%) | 7/28 (25%) 6/24 (25%) 6/24 (25%) 6/23 (26%) |
|FIRST INCIDENCE (DAYS) | 413 408 525 334 | 674 525 650 534 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.126N P=0.289 P=0.198N P=0.231N | P=0.193 P=0.311 P=0.377N P=0.208 |
|INCIDENTAL TUMOR | P=0.479N P=0.319N P=0.104N P=0.358N | P=0.311 P=0.530 P=0.190N P=0.378 |
|LOGISTIC REGRESSION | P=0.412N P=0.303N P=0.105N P=0.324N | P=0.465 P=0.489N P=0.237N P=0.539N |
|COCHRAN-ARMITAGE | P=0.463N | P=0.359 |
|FISHER EXACT | P=0.263N P=0.107N P=0.335N | P=0.500 P=0.194N P=0.418 |
|=================================================================================================================================|
| |
|All Organs |
| Mesothelioma: Benign, Malignant, NOS |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 3/50 (6%) 4/50 (8%) 0/50 (0%) 1/50 (2%) | 0/50 (0%) 0/50 (0%) 0/50 (0%) 0/50 (0%) |
|ADJUSTED (b) | 10.6% 11.0% 0.0% 3.8% | 0.0% 0.0% 0.0% 0.0% |
|TERMINAL (d) | 1/17 (6%) 0/10 (0%) 0/16 (0%) 0/17 (0%) | 0/28 (0%) 0/24 (0%) 0/24 (0%) 0/23 (0%) |
|FIRST INCIDENCE (DAYS) | 436 469 --- 693 | --- --- --- --- |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.137N P=0.422 P=0.121N P=0.281N | (e) (e) (e) (e) |
|INCIDENTAL TUMOR | P=0.243N P=0.546 P=0.145N P=0.384N | (e) (e) (e) (e) |
|LOGISTIC REGRESSION | P=0.161N P=0.600 P=0.115N P=0.304N | (e) (e) (e) (e) |
|COCHRAN-ARMITAGE | P=0.166N | (e) |
|FISHER EXACT | P=0.500 P=0.121N P=0.309N | (e) (e) (e) |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 26
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 48/50 (96%) 49/50 (98%) 46/50 (92%) | 45/50 (90%) 49/50 (98%) 49/50 (98%) 47/50 (94%) |
|ADJUSTED (b) | 100.0% 100.0% 100.0% 100.0% | 97.8% 100.0% 98.0% 95.9% |
|TERMINAL (d) | 17/17 (100%) 10/10 (100%) 16/16 (100%) 17/17 (100%)| 27/28 (96%) 24/24 (100%) 23/24 (96%) 21/23 (91%) |
|FIRST INCIDENCE (DAYS) | 413 274 454 497 | 534 485 326 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.039N* P=0.107 P=0.509N P=0.172N | P=0.159 P=0.076 P=0.092 P=0.076 |
|INCIDENTAL TUMOR | P=0.023N* P=0.280N (e) P=0.055N | P=0.621 P=0.139 P=0.081 P=0.552 |
|LOGISTIC REGRESSION | P=0.066N P=0.339N (e) P=0.055N | P=0.603N P=0.159 P=0.086 P=0.392 |
|COCHRAN-ARMITAGE | P=0.047N* | P=0.582 |
|FISHER EXACT | P=0.247N P=0.500N P=0.059N | P=0.102 P=0.102 P=0.357 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 40/50 (80%) 38/50 (76%) 34/50 (68%) 40/50 (80%) | 28/50 (56%) 23/50 (46%) 23/50 (46%) 30/50 (60%) |
|ADJUSTED (b) | 92.4% 94.2% 88.1% 97.3% | 64.9% 58.9% 62.8% 73.5% |
|TERMINAL (d) | 14/17 (82%) 8/10 (80%) 12/16 (75%) 16/17 (94%) | 13/28 (46%) 9/24 (38%) 11/24 (46%) 13/23 (57%) |
|FIRST INCIDENCE (DAYS) | 413 408 213 334 | 433 525 583 534 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.172N P=0.155 P=0.254N P=0.360N | P=0.082 P=0.484N P=0.468N P=0.160 |
|INCIDENTAL TUMOR | P=0.487 P=0.516N P=0.095N P=0.592 | P=0.139 P=0.250N P=0.214N P=0.341 |
|LOGISTIC REGRESSION | P=0.476 P=0.488N P=0.126N P=0.591N | P=0.158 P=0.216N P=0.246N P=0.398 |
|COCHRAN-ARMITAGE | P=0.424 | P=0.187 |
|FISHER EXACT | P=0.405N P=0.127N P=0.598N | P=0.212N P=0.212N P=0.420 |
|=================================================================================================================================|
DATE: 04/04/96 EXPERIMENT: 05158 TEST: 03 PAGE 27
STATISTICAL ANALYSIS OF PRIMARY TUMORS IN RATS(FISCHER344) -- 7-5MOLYBDENUM TRIOXIDE
TERMINAL SACRIFICE AT 105 WEEKS
|=================================================================================================================================|
| | | |
| | MALES | FEMALES |
| | | |
|DOSE | CONTROL 10 MG/M3 30 MG/M3 100 | CONTROL 10 MG/M3 30 MG/M3 100 |
| | MG/M3 | MG/M3 |
|=================================================================================================================================|
| |
|All Organs |
| Malignant and Benign Tumors |
| |
|---------------------------------------------------------------------------------------------------------------------------------|
|TUMOR RATES | # # # # | # # # # |
|----------- | | |
|OVERALL (a) | 50/50 (100%) 50/50 (100%) 50/50 (100%) 49/50 (98%) | 48/50 (96%) 50/50 (100%) 49/50 (98%) 49/50 (98%) |
|ADJUSTED (b) | 100.0% 100.0% 100.0% 100.0% | 100.0% 100.0% 98.0% 98.0% |
|TERMINAL (d) | 17/17 (100%) 10/10 (100%) 16/16 (100%) 17/17 (100%)| 28/28 (100%) 24/24 (100%) 23/24 (96%) 22/23 (96%) |
|FIRST INCIDENCE (DAYS) | 413 274 213 334 | 433 485 326 527 |
|-----------------------| | |
|STATISTICAL TESTS (f) | | |
|-----------------------| | |
|LIFE TABLE | P=0.077N P=0.071 P=0.540 P=0.295N | P=0.160 P=0.133 P=0.188 P=0.098 |
|INCIDENTAL TUMOR | P=0.451N (e) (e) (e) | P=0.627N P=0.557 P=0.492 P=0.739N |
|LOGISTIC REGRESSION | P=0.451N (e) (e) (e) | P=0.650N P=0.600 P=0.614 P=0.709 |
|COCHRAN-ARMITAGE | P=0.221N | P=0.627 |
|FISHER EXACT | P=1.000N P=1.000N P=0.500N | P=0.247 P=0.500 P=0.500 |
|=================================================================================================================================|
(a) Number of tumor-bearing animals / number of animals examined at site.
(b) Kaplan-Meier estimated lifetime tumor incidence after adjustment for
intercurrent mortality.
(d) Observed incidence at terminal kill.
(f) Beneath the control incidence are the P-values associated with the trend
test. Beneath the dosed group incidence are the P-values corresponding to
pairwise comparisons between the controls and that dosed group. The life
table analysis regards tumors in animals dying prior to terminal kill as
being (directly or indirectly) the cause of death. The incidental tumor
test regards these lesions as non-fatal. Logistic regression is an alternative
method for analyzing the incidence of non-fatal tumors. The Cochran-Armitage
and Fisher's exact tests compare directly the overall incidence rates.
For all tests, a negative trend is indicated by "N".
(e) Value of Statistic cannot be computed.
(I) Interim sacrifice
(T) Terminal sacrifice
# Tumor rates based on number of animals necropsied.
* To the right of any statistical result, indicates significance at (P<=0.05).
** To the right of any statistical result, indicates significance at (P<=0.01).